Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Health Economics

Prediabetes as an indication for GLP-1 therapy. Clarifying evidence thresholds and clinical guardrails

International Journal of Obesity volume 50, page 478 (2026)Cite this article

Subjects

To the Editor:

The Perspective on prediabetes as a potential indication for GLP-1 therapy raises an important clinical and policy question [1]. Any new indication should rest on outcomes that matter for patients and payers and on a clear definition of who benefits most.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Apovian CM. Prediabetes: a new indication for GLP-1s? Int J Obes 2025. https://doi.org/10.1038/s41366-025-01930-2

  2. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. https://doi.org/10.1056/NEJMoa012512.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. Three years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399–409. https://doi.org/10.1016/S0140-6736(17)30069-7.

    Article  PubMed  CAS  Google Scholar 

  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–32. https://doi.org/10.1056/NEJMoa2307563.

    Article  PubMed  CAS  Google Scholar 

  5. Bannuru RR. ADA Professional Practice Committee. Introduction and methodology: Standards of Care in Overweight and Obesity—2025. BMJ Open Diabetes Res Care. 2025;13:e004928. https://doi.org/10.1136/bmjdrc-2025-00492810/10/2025.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, New Taipei City Hospital, New Taipei City, Taiwan

    Jian-Ying Wang

Authors
  1. Jian-Ying Wang
    View author publications

    Search author on:PubMed Google Scholar

Contributions

JY Wang conceived the topic, reviewed the literature, interpreted the findings, drafted and approved the final manuscript.

Corresponding author

Correspondence to Jian-Ying Wang.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, JY. Prediabetes as an indication for GLP-1 therapy. Clarifying evidence thresholds and clinical guardrails. Int J Obes 50, 478 (2026). https://doi.org/10.1038/s41366-025-01959-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41366-025-01959-3

Search

Advanced search

Quick links